7:04AM ISIS Pharm announces patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67% in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (ISIS) 29.23 : Co announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67% in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA).
Patients treated with ISIS-CRPRx showed improvements in signs and symptoms of RA; however, these improvements were not statistically significant when compared to those observed in patients in the placebo group, which demonstrated a higher than expected response in both symptom score and CRP reduction. A Phase 2 study of ISIS-CRPRx in patients with atrial fibrillation is currently ongoing with data anticipated in the first half of 2014.
Market Data 
Markets 
AI
